Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | NNMT | P40261 | 5/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | STAMBP | O95630 | 1/20 | 0.36 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640966 | 1.00 | PARP1 (0.44) | PARP1NNMTCHEK2HSD11B1MME | |
| SCHEMBL29737900 | 0.84 | MME (0.43) | HSD11B1MMESMN1; SMN2HDAC6ALDH1A1 | |
| SCHEMBL1759160 | 0.84 | MME (0.43) | HSD11B1MMESMN1; SMN2HDAC6ALDH1A1 | |
| SCHEMBL2009039 | 0.82 | HSD11B1 (0.40) | HSD11B1MMESMN1; SMN2HDAC6ALDH1A1 | |
| SCHEMBL12653303 | 0.79 | ALDH1A1 (0.36) | HSD11B1MMEHDAC6ALDH1A1RXFP1 | |
| SCHEMBL12618978 | 0.79 | ALDH1A1 (0.36) | HSD11B1MMEHDAC6ALDH1A1RXFP1 | |
| SCHEMBL25276880 | 0.74 | HPGDS (0.44) | HSD11B1MMEHDAC6NTRK1HPGDS | |
| SCHEMBL4228892 | 0.74 | CYP2C9 (0.48) | SMN1; SMN2ALDH1A1KDM4EHPGDRAB9A | |
| SCHEMBL2301543 | 0.71 | MAPK1 (0.43) | PARP1NNMTCHEK2SMN1; SMN2GDA | |
| SCHEMBL476587 | 0.71 | HDAC6 (0.66) | HSD11B1SMN1; SMN2HDAC6ALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4225739-B1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4225739-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-08-16 | — | — | EP | claimed |
| WO-2022076495-A1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | WO | claimed |
| US-8703796-B2 | 3H-imidazo [4, 5-B] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | claimed |
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | claimed |
| EP-2350073-A1 | 3H-IMIDAZO[4,5-b]PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-08-03 | — | — | EP | claimed |
| WO-2010034799-A1 | 3H-IMIDAZ0 [4, 5-B] PYRIDINE- 6 -CARBOXAMIDES AS ANTI -INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | claimed |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025264672-A1 | INHIBITORS OF MOBILIZED COLISTIN RESISTANCE ENZYME (MCR-1) AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11939343-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| EP-2649071-B1 | Imidazo(4,5-b)pyridine-6-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2015-07-08 | — | — | EP | disclosed |
| US-7960394-B2 | 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20080275069-A1 | Quinazoline Derivative | MSD K.K. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007022305-A2 | 2-AMINOIMIDAZOPYRIDINES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1658289-A2 | 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005021544-A2 | N3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939343-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | PARP1 536/4885NNMT 1975/4885CHEK2 251/4885 |
| US-20080275069-A1 | Quinazoline Derivative | HRH3, HRH4, HRH2 | PARP1 2041/4885NNMT 752/4885CHEK2 334/4885 |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | PARP1 2722/4885NNMT 773/4885CHEK2 317/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | PARP1 313/4885NNMT 13/4885CHEK2 1455/4885 |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | PARP1 2722/4885NNMT 773/4885CHEK2 317/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | PARP1 3837/4885NNMT 2245/4885CHEK2 3654/4885 |
| US-20120115902-A1 | 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents | MAP4, MAPRE2, IL4 | PARP1 2003/4885NNMT 1022/4885CHEK2 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.